Written by The Prostate Cancer Treatment Market is witnessing steady development alongside improvements in cancer treatment technologies and growing investment in prostate cancer research. Market Research Future estimates that the market will reach USD 14.52 billion by 2035 from USD 8.31 billion in 2024, reflecting a CAGR of 5.2% over the forecast period.
Rising prostate cancer incidence, an aging population, and greater awareness of screening are important factors supporting market growth. Healthcare organizations are also investing in advanced treatment approaches, including targeted therapies, hormone-based treatments, radiation techniques, and immunotherapy.
Treatment options covered in the market include surgery, radiation therapy, hormonal therapy, chemotherapy, and immunotherapy. Surgery currently holds the largest share, while immunotherapy is developing rapidly as research and investment in novel cancer treatments increase. Injection is the dominant administration route, although oral therapies are gaining attention because of their convenience.
Hospitals remain the largest end users because they provide comprehensive surgical, radiation, and systemic treatment services. Regionally, North America leads with about 45% share, while Europe contributes around 30% and Asia-Pacific approximately 20%. Increasing healthcare access and cancer-care investments are expected to create further opportunities across emerging markets.